Influence of drug transporter expression on the pharmacokinetics of the HIV protease inhibitor Kaletra (lopinavir/ritonavir) and on the concentration relations between plasma, blood cells, saliva and urine

Trial Profile

Influence of drug transporter expression on the pharmacokinetics of the HIV protease inhibitor Kaletra (lopinavir/ritonavir) and on the concentration relations between plasma, blood cells, saliva and urine

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2009

At a glance

  • Drugs Lopinavir/ritonavir (Primary)
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 12 Feb 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov, last updated 12-2-2009.
    • 12 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top